Douma Joeri A J, Smulders Yvo M
VU medisch centrum, afd. Interne Geneeskunde, Amsterdam.
Ned Tijdschr Geneeskd. 2015;159:A9132.
Many physicians are resistant to the idea of prescribing loperamide for acute infectious traveller's diarrhoea and community-acquired diarrhoea because of the fear of possible adverse effects. Large randomized trials with loperamide, either alone or as an adjunct to antibiotic treatment, have in fact revealed positive rather than negative effects. International guidelines now often support the use of loperamide for the treatment of infectious diarrhoea without dysentery. There seems to be no reason to systematically avoid loperamide in patients with dysentery, but caution is advised. Loperamide can be used as monotherapy or as an adjunct to antibiotic treatment in immunocompetent adults with acute infectious traveller's diarrhoea or community-acquired diarrhoea without severe comorbidities. This can reduce both the frequency of diarrhoea and the time until the diarrhoea stops without the risk of severe complications.
许多医生因担心可能出现的不良反应,而不愿为急性感染性旅行者腹泻和社区获得性腹泻患者开具洛哌丁胺。事实上,单独使用洛哌丁胺或作为抗生素治疗辅助药物的大型随机试验显示的是积极而非消极的效果。现在国际指南常常支持使用洛哌丁胺治疗非痢疾性感染性腹泻。对于痢疾患者,似乎没有理由系统性地避免使用洛哌丁胺,但建议谨慎使用。洛哌丁胺可用于无严重合并症的急性感染性旅行者腹泻或社区获得性腹泻的免疫功能正常的成年人,作为单一疗法或抗生素治疗的辅助药物。这既能减少腹泻次数,又能缩短腹泻停止的时间,且无严重并发症风险。